Creutzfeldt-Jakob disease (CJD) is a fatal neurologic disorder in humans. CJD is one of a group of conditions known as transmissible spongiform encephalopathies (TSEs), or prion diseases, that are believed to be caused by abnormally configured, host-encoded prion proteins that accumulate in the central nervous tissue (1) . CJD has an annual incidence of approximately 1 case per million population in the United States (1) and occurs in three forms: sporadic, genetically determined, and acquired by infection. In the latter form, the incubation period is measured typically in years. Recent evidence that prion infection can cross the species barrier between humans and cattle has raised increasing public health concerns about the possible transmission to humans of a TSE among deer and elk known as chronic wasting disease (CWD) (2) . During 1993-1999, three men who participated in wild game feasts in northern Wisconsin died of degenerative neurologic illnesses. This report documents the investigation of these deaths, which was initiated in August 2002 and which confirmed the death of only one person from CJD. Although no association between CWD and CJD was found, continued surveillance of both diseases remains important to assess the possible risk for CWD transmission to humans.
Case Reports
Case 1. In December 1992, a Wisconsin man aged 66 years with a history of seizures since 1969 sought treatment for recurring seizures, increasing forgetfulness, and worsening hand tremors. Electroencephalographic (EEG) examination demonstrated focal epileptiform activity and nonspecific diffuse abnormalities, but no specific diagnosis was made. In February 1993, he was hospitalized for increasing confusion, ataxia, and movement tremors of his extremities. A magnetic resonance image (MRI) demonstrated mild, nonspecific enhancement along the inferior parasagittal occipital lobe.
A repeat EEG showed bifrontal intermittent, short-interval, periodic sharp waves, suggesting a progressive encephalopathy; a diagnosis of CJD was suspected. The man died later that month; neuropathologic examination of brain tissue during autopsy indicated subacute spongiform encephalopathy, compatible with CJD.
The man was a lifelong hunter who ate venison frequently. He hunted primarily in northern Wisconsin but also at least once in Montana. He hosted wild game feasts at his cabin in northern Wisconsin from 1976 until shortly before his death. Fixed brain tissue obtained during the autopsy was sent for analysis to the National Prion Disease Pathology Surveillance Center (NPDPSC) and reexamined at the institution where the autopsy was conducted. Histopathologic examination did not substantiate the diagnosis of prion disease. In addition, 27 brain tissue sections were negative for prions by immunostaining despite positive antibody reactions against other proteins (controls), which indicated that other epitopes in the tissue samples were preserved.
Case 2. In May 1999, a Minnesota man aged 55 years with no previous history of a neurologic disease sought evaluation and treatment following a 3-month history of progressive difficulty in writing and unsteadiness of gait. A computerized tomography (CT) scan and MRI examination of his head did not indicate any abnormality. In June 1999, he was hospitalized following onset of dementia, speech abnormalities, and myoclonic jerking. An EEG indicated left-hemispheric periodic sharp waves and moderate generalized background slowing; CJD was diagnosed clinically. In July 1999, following worsening symptoms and development of right upper extremity dystonia, the patient died. Neuropathologic evaluation of brain tissue during autopsy demonstrated widespread subcortical spongiform lesions, consistent with CJD.
The man was not a hunter but had a history of eating venison. He made an estimated 12 visits to the cabin where the wild game feasts were held, but he participated in only one feast during the mid-1980s. Sections of fixed and frozen brain tissue obtained during autopsy were analyzed at NPDPSC, and prion disease was confirmed by immunohistochemical and Western blot testing. The Western blot characteristics and prion disease phenotype in this patient were consistent with the most common form of sporadic CJD, classified as M/M (M/V) 1 (3) . Subsequent genetic typing confirmed the presence of methionine homozygosity (M/M) at codon 129 of the patient's prion protein gene.
Case 3. In June 1992, a Wisconsin man aged 65 years sought treatment for progressive slowing of speech, worsening memory, and personality changes. By January 1993, his speech was reduced to one-word utterances. Neurologic examination showed a flat affect, decreased reflexes, and apraxia. A CT head scan showed mild atrophy, and an EEG was normal. Pick's disease was diagnosed. By May, he was unable to perform any daily living activities; he died in August 1993. Neuropathologic evaluation of brain tissue during autopsy showed symmetrical frontal lobe cerebral cortical atrophy and mild temporal lobe atrophy. No Pick's bodies or spongiform lesions were observed.
The man had a history of eating venison and participated regularly in wild game feasts held at the cabin owned by patient 1. He was a lifelong hunter and hunted mostly in Wisconsin but also in Wyoming and British Columbia. No game was brought to the wild game feasts from his hunting trips outside of Wisconsin. Examination of fixed brain tissue sent to NPDPSC demonstrated no lesions indicative of CJD, and immunohistochemical testing with antibody to the prion protein did not demonstrate the granular deposits seen in prion diseases.
These feasts typically involved 10-15 participants and usually occurred on weekends before or during hunting seasons in the fall and occasionally in the spring. Wild game brought to these feasts usually were harvested in Wisconsin, but three men who attended these feasts reported hunting in the western United States and bringing game back to Wisconsin. These activities took place in Colorado (near the towns of Cortez, Trinidad, Collbran, Durango, and Meeker), Wyoming (near the towns of Gilette and Cody), and Montana (near the town of Malta). CWD was not known to be endemic in these areas at the time that these hunting activities took place.
Information was obtained for 45 (85%) of 53 persons who were identified as possibly participating in the wild game feasts; all were male. Information was obtained by direct interview or from family members of decedents. Of the 45 persons, for whom information was obtained, 34 were reported to have attended wild game feasts. Seven of the 34 feast attendees were deceased, including the three patients. None of the four other decedents had a cause of death attributed to or associated with a degenerative neurologic disorder. None of the living participants had any signs or symptoms consistent with a degenerative neurologic disorder.
Editorial Note: CWD was first described in the United States in the 1960s and classified as a TSE in 1978. Previously localized to a contiguous endemic area in northeastern Colorado and southeast Wyoming, since 2000, CWD has been found in free-ranging deer or elk in Illinois, Nebraska, New Mexico, South Dakota, Wisconsin, and outside the previously known endemic areas of Colorado and Wyoming. CWD has been identified also in captive deer or elk in Colorado, Kansas, Minnesota, Montana, Nebraska, Oklahoma, South Dakota, and Wisconsin (4). Because a variant form of CJD, with specific neuropathologic and molecular characteristics that distinguish it from sporadic CJD, has been associated with eating cattle products infected with a prion that causes bovine spongiform encephalopathy (5), concern has been raised about the possibility that the prion associated with CWD might be transmitted to humans in a similar way.
In this investigation, because only one of the three cases in Wisconsin had neuropathologic confirmation of a prion disease, no association could be made between case participation in the wild game feasts and the development of CJD. Although patient 2 had confirmed CJD, he was unlikely to have eaten CWD-infected venison at these feasts because venison and other game from outside Wisconsin that was served at these feasts did not originate from known CWD-endemic areas, and the man participated in the feasts only once. In addition, the prion disease in this case was consistent with the most common form of sporadic CJD, without apparent unusual neuropathologic or molecular characteristics that might occur if the prion related to CWD had been responsible for the disease.
The findings in this report are subject to at least two limitations. First, not all members participating in wild game feasts could be identified, and not all persons listed as participating could be contacted for interviews. Second, interviews that were conducted required recall of events that occurred up to 25 years ago, limiting the detail or accuracy of events. However, the similar responses obtained from different sources support the accuracy of the investigation findings.
A previous investigation of unusually young CJD patients in whom the transmission of CWD was suspected also did not provide convincing evidence for a causal relationship between CWD and CJD (2). However, limited epidemiologic investigations cannot rule out the possibility that CWD might play a role in causing human illness. Ongoing surveillance of CJD, particularly in states with CWD, is important to assess the risk, if any, for CWD transmission to humans. Because the confirmation of CJD and the detection of a new prion disease require neuropathologic study of brain tissue, physicians are encouraged to contact NPDPSC (http:// www.cjdsurveillance.com; telephone, 216-368-0587) to confirm diagnoses of CJD and to distinguish its various subtypes. Because of the known severity of TSEs in humans and the possibility that the CWD prion can affect humans, animals with evidence of CWD should be excluded from the human food or animal feed chains. Hunters and wild venison consumers should follow precautionary guidelines available from the Wisconsin Department of Agriculture, Trade, and Consumer Protection (http://datcp.state.wi.us/core/consumerinfo) to prevent potential exposures to the CWD agent.
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Public Health and Aging
Atrial Fibrillation as a Contributing Cause of Death and Medicare Hospitalization -United States, 1999
Stroke is the leading cause in the United States of serious long-term disability and the third leading cause of death. One of the major risk factors for stroke is atrial fibrillation (AF), a common cardiac disorder characterized by cardiac arrhythmia and the absence of coordinated contractions, which increases the risk for blood stasis, clot formation, and embolic stroke. AF affects approximately 2.2 million adults in the United States (1, 2) and is the most common sustained heart rhythm disturbance observed in clinical practice (3) . The rate of AF increases with age, from <1% among persons aged <60 years to approximately 10% among persons aged >80 years (4) . The frequency with which AF is reported on death certificates as a contributing cause of death has increased since 1980 (5) . To assess the burden of AF-related deaths and hospitalizations among U.S. residents, CDC analyzed national and state multiple-cause mortality statistics and Medicare hospital claims for persons with AF in 1999 (the latest year for which data were available) for the 50 states and the District of Columbia. The findings indicate that AF as a contributing cause of death and hospitalization affects primarily persons aged >75 years and that death and hospitalization rates vary by state. Public and medical education are needed to prevent and reduce AF-related disability and death.
National and state multiple-cause mortality statistics were obtained from death certificates in state vital statistics offices and compiled by CDC. AF-related deaths are those for which the contributing cause of death* (any one of the 20 possible conditions listed on the death certificate) listed by a physician or a coroner is classified as code I48 according to the International Classification of Diseases, Tenth Revision (ICD-10). Among decedents who had AF, the proportion of those who had an underlying cause of death listed as AF (ICD-10 I48), coronary heart disease (ICD-10 I20-I25), or stroke (ICD-10 I60-I69) also was assessed. Demographic data (age, sex, and race/ethnicity) on death certificates were reported by funeral directors or provided by family members of the decedent. The denominators for death rates were obtained from 1999 census records and included only U.S. residents.
Medicare AF-related death rates for groups defined by age, sex, race/ ethnicity, and state were determined by dividing the number of deaths by the population at risk (denominator) in each group. Rates of hospitalizations among Medicare enrollees aged >65 years with AF for each group were determined by dividing the number of hospitalizations by the population at risk (denominator) in the group. Age-adjusted death rates (per 100,000 population) and hospitalization rates (per 1,000 Medicare enrollees) were calculated by using the 2000 U.S. standard population (6) .
In 1999, a total of 66,875 deaths with AF as a contributing cause occurred, resulting in an age-adjusted death rate of 24.7 per 100,000 population. Of these deaths, 56,138 (84.0%) were among persons aged >75 years. The greatest proportion of these AF-related deaths occurred among persons aged >85 years (47.4%), followed by those aged 75-84 years (36.6%), aged 65-74 years (12.3%), and aged <65 years (3.7%). Agespecific death rates increased for successive age groups (Table 1) . Age-adjusted death rates for AF were highest among whites (25.7) and blacks (16.4) and higher for men (34.7) than women (22.8). In 1999, for all decedents who had AF, the most common underlying causes of death were coronary heart disease (28.0%), AF (12.4%), and stroke (10.8%).
In 1999, a total of 1,765,304 hospitalizations (137.1 per 1,000 Medicare enrollees) were reported among persons with AF in the Medicare population (Table 1 ). Rates increased among successive age groups. The rate of hospitalization among persons with AF was higher among whites (142.7) than among blacks (100.4). Although 55.7% of these hospitalizations were among women, men (162.9) had a higher rate of AF-related hospitalization than women (121.2). The most common diseases listed as the primary diagnosis for persons hospitalized with AF were congestive heart failure (11.8%), followed by AF (10.9%), coronary heart disease (9.9%), and stroke (4.9%). The state-specific age-adjusted death rates for AF ranged from 13.1 in Arizona to 37.4 in Maryland (Figure) . The ageadjusted rate of hospitalizations among persons with AF ranged from 90.2 in New Mexico to 177.5 in West Virginia (Table 2 ).
Editorial Note: The findings in this report confirm that AF is a contributing cause of death among older persons, particularly those aged >75 years, and that state-specific AF-related death rates vary. These findings are consistent with other trends of AF-related deaths (5) . Patterns in the rate of AF-related hospitalization among Medicare enrollees are similar to those for death rates. The high proportion of AF-related deaths and hospitalizations occurring among persons aged >75 years suggests that as the population ages, AF might be diagnosed more frequently. A cohort study of hospitalized Medicare patients indicated that medical costs were greater for patients with AF than for those without AF (7). In addition, effective therapies for AF reduced the risk for stroke by >70%. Patients who have coronary heart disease, hypertensive disease, or stroke diagnosed and who live longer might be at risk for AF if effective therapy is not maintained (8) . Serious complications among patients with uncontrolled AF also can include congestive heart failure, myocardial infarction, and thrombotic stroke. Initial treatment of AF should be directed at controlling the ventricular rate with a calcium channel blocker, betablocker, or digitalis (3). Medical or electrical cardioversion to restore sinus rhythm is the next step in patients who remain in AF. Effective therapies in preventing stroke and cardiovascular complications include anticoagulation, heart rate control, conversion of AF to normal heart rhythm, and catheter-based and surgical interventions (3) .
Educating the public to recognize the signs of cardiac arrhythmia can help identify persons with AF. Persons can identify an irregular heartbeat by monitoring their wrist pulse for 1 minute. The irregularity of these beats is detected and the next beat cannot be predicted. Persons who identify the signs of cardiac arrhythmia should seek medical care to determine the presence of AF or other heart disorders. The Research Center for Stroke and Heart Disease (http://www. strokeheart.org), has initiated the educational campaign, "Take Your Pulse For Life." This initiative recommends that persons, particularly those aged >55 years, monitor their pulse for 1 minute the first day of every month. Assessing whether a patient has AF can be easy and inexpensive through using electrocardiography (ECG) (3); the availability of more advanced diagnostic tools, such as ECG monitoring, might contribute to AF diagnosis in persons suspected to have cardiac arrhythmia. Delay in diagnosis occurs when the rhythm has not been documented specifically and additional monitoring is necessary (3). All persons should know how to take a pulse for themselves or their family members.
The findings in this report are subject to at least two limitations. First, data are subject to misclassification of race/ ethnicity both in the population census and on death certificates, possibly resulting in overreporting among blacks and whites and underreporting among other racial/ethnic groups (9). Second, it was not possible to determine the accuracy of physician or administrative reporting, the validity of the ICD codes, or multiple hospitalizations on Medicare hospital claims.
Because AF is one of the major treatable risk factors for stroke, prevention of AF through public and medical education for early identification and appropriate treatment should become an important focus of public health efforts to reduce stroke-related deaths and disability. Prevention efforts should include broad-based public health efforts to increase public awareness of AF and to foster timely and appropriate diagnostic evaluation and effective treatment from health-care providers. Readiness Force* and the WTC Environmental Assessment Working Group † , assessed the composition of outdoor and indoor settled surface and airborne dust in residential areas around the WTC and in comparison areas. This report summarizes the results of the investigation, which found 1) similar levels of airborne total fibers in lower and in upper Manhattan, 2) greater percentage levels of synthetic vitreous fibers (SVF) and mineral components of concrete and building wallboard in settled dust of residential areas in lower Manhattan than in upper Manhattan, and 3) low levels of asbestos in some settled surface dust in lower Manhattan residential areas (1) . Based in part on the results of this investigation, the U.S. Environmental Protection Agency (EPA) is cleaning and sampling residential areas as requested by lower Manhattan residents. In addition, to assess any short-or longterm health effects of smoke, dust, and airborne substances around the WTC site, DOHMH and ATSDR are developing a registry that will track the health of persons who were most highly exposed to these materials. During November 4-December 11, 2001, air and settled surface dust samples were collected in and around 30 residential buildings within three concentric circles surrounding the WTC site in lower Manhattan, including 59 residential units (2) . In addition, five residential units in four buildings located north of 59th Street (approximately 5 miles northeast of the WTC site) were sampled for purposes of comparison. Attention was focused on building material constituents 1) that have irritant properties (e.g., SVF, including fiberglass and gypsum) or might have negative long-term health effects (e.g., crystalline silica and asbestos) and 2) that were reasonably presumed to be either in the initial WTC collapse dust cloud or in dust generated by subsequent rescue and recovery activities at the WTC site. All samples collected during the investigation were analyzed for the presence of asbestos, SVF, crystalline mineral components of concrete (e.g., silica, calcite, and portlandite), and crystalline mineral components of building wallboard (e.g., gypsum, mica, and halite).
Potential Exposures to
At each sampling location, time-weighted air sampling was conducted for three or four particulate matter (PM) fractions (i.e., PM 100 microns, 10 microns, 4 microns, and 2.5 microns) (3) (4) (5) . Each PM fraction was analyzed for crystalline minerals by using X-ray diffraction (XRD) analysis (6) .
The XRD analysis for crystalline minerals was semiquantitative (i.e., estimated). Air samples for fibers were analyzed first by phase contrast microscopy (PCM) (5) . If the concentration of total fibers was higher than the maximum concentration of fibers found in the comparison homes (0.003 fibers per cubic centimeter of air [f/cc]), the sample was re-analyzed for asbestos fibers by using transmission electron microscopy (TEM) (5) . In addition, scanning electron microscopy (SEM) to look for SVF was used for PCM fiber counts >0.003 f/cc if the settled surface dust sample from that area contained SVF.
Settled surface dust samples also were taken at each sampling location and analyzed for crystalline minerals and fibers ( Figure) . Fiber analysis of settled dust samples for asbestos and SVF was conducted by using polarized light microscopy (PLM) (7) . If asbestos levels were below the detection limit (i.e., <1%), samples were re-analyzed by using TEM (7) . The dust samples also were analyzed for crystalline mineral content by using XRD.
Air Sampling Results
For 111 (94.9%) of the 117 air samples, the concentrations of fibers found in lower Manhattan residential areas were similar to the concentration of fibers found in comparison areas (<0.003 f/cc). The six lower Manhattan areas that had elevated total fiber counts were re-examined by TEM and SEM to determine the types of fibers; the results indicated that neither asbestos nor SVF (e.g., fiberglass) contributed to the elevated total fiber counts.
Air sampling results for minerals detected quartz and other building material constituents in lower Manhattan. No other forms of crystalline silica were detected in any air samples except for a one-time detection of cristobalite (15 micrograms per cubic meter [µg/m 3 ] § ). The estimated concentrations of these minerals in air were low. In some locations, mineral com- 
Settled Surface Dust Results
In lower Manhattan, asbestos and SVF were found in some indoor settled dust samples from residential units and common areas ( Editorial Note: Exposure to substantial amounts of SVF, mineral components of concrete, and mineral components of building wallboard might cause skin rashes, eye irritation, and upper respiratory irritation, all of which were reported more frequently than expected seasonal rates by community members and first responders after the collapse of the WTC towers (8) (9) (10) . If the reported irritant effects were associated with WTC-related materials, these effects would subside once exposure to SVF, mineral components of concrete, and mineral components of building wallboard ceased. Persons with pre-existing heart or lung diseases (e.g., asthma) or a previous history of occupational exposure to these materials might be more sensitive to their irritant effects.
Settled surface dust might become airborne if disturbed, potentially causing exposures to occur through inhalation. Several worst-case assumptions were made to assess the potential long-term public health risks for inhaling airborne asbestos and quartz. These assumptions included 1) that no SVF PLM * All dust samples were analyzed initially by using polarized light microscopy (PLM); transmission electron microscopy (TEM) analysis was performed to confirm the absence of asbestos if not detected by PLM analysis. † Detected by either PLM or TEM (reported as <1% or more); calculated from the total number of dust samples. § The highest value detected at a location (PLM or TEM). ¶ Calculated from the number of SVF PLM samples. ** For some locations, an additional co-located sample was obtained; the range shown considers the highest measured value for each sampling location. † † One residential unit had an extra settled surface dust sample, taken from a window sill, which contained 40% SVF by PLM.
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cleaning of indoor spaces had occurred or would occur, 2) that all airborne fibers were asbestos, and 3) that the highest levels detected during sampling represented long-term air levels. Under these worst-case conditions, prolonged exposure (i.e., decades) to airborne asbestos and quartz might increase the long-term risk for persons developing lung cancer and other adverse lung health effects (approximately one additional case per 10,000 persons exposed). However, persons who clean their residences frequently as recommended (1) or who participate in the EPA cleaning and sampling program are unlikely to be exposed to worst-case conditions.
The findings of this investigation are subject to at least two limitations. First, the results do not necessarily reflect conditions found in other buildings, the time period immediately after the collapse, or the time period after December 12, when the sampling was completed. Second, a limited number of samples were obtained from comparison areas to determine NYC background levels of asbestos, SVF, mineral components of concrete, and mineral components of building wallboard. The comparison area results might not reflect NYC background levels. Following the investigation, DOHMH and ATSDR made three recommendations (1). First, because more asbestos, SVF, mineral components of concrete and building wallboard were found in settled surface dust in lower Manhattan residential areas than in comparison residential areas, residents of lower Manhattan were advised to continue cleaning frequently with high-efficiency particulate air (HEPA) filter vacuums and damp cloths/mops to reduce the potential for exposure. Second, to ensure the effectiveness of the recommended cleaning, DOHMH and ATSDR recommended additional monitoring of residential areas in lower Manhattan and an investigation to define background levels specific to NYC for asbestos, SVF, mineral components of concrete, and mineral components of building wallboard. EPA is implementing this recommendation and conducting this investigation. Finally, lower Manhattan residents concerned about possible WTCrelated dust in their residential areas were advised to request cleaning and testing from EPA no later than December 31, 2002. EPA is conducting the requested cleaning and testing of lower Manhattan residential areas. DOHMH and ATSDR are developing a registry of those persons who were most highly exposed, including persons living, working, or attending school in lower Manhattan; persons who responded to the emergency; persons working at the WTC site or the Staten Island landfill following the attacks; and persons working in buildings that were damaged or destroyed in the attacks. The registry will track the health of participants to determine whether their exposures to smoke, dust, and airborne substances around the WTC site might have any short-or long-term impacts on their physical health. Additionally, the registry is intended to track the mental health of the approximately 100,000-200,000 persons who might enroll. 
Smallpox Vaccine Adverse Events Among Civilians -United States, January 24-February 18, 2003
During the civilian smallpox vaccination program, CDC and state health departments are conducting surveillance for vaccine-associated adverse events. In the first stage of the program, active surveillance is being conducted for potentially life-threatening, moderate-to-severe, and other serious adverse events and for vaccinia transmission to contacts of vaccinees (1) (Table) . Nonserious events are reported via passive surveillance and are expected to be underreported. This report summarizes smallpox vaccine adverse events reported among civilians vaccinated as of February 14, 2003, and received by CDC from the Vaccine Adverse Event Reporting System (VAERS) as of February 18.
Potentially life-threatening and moderate-to-serious events are classified on the basis of evidence in support of the reported diagnoses. For probable cases, other causes are excluded, and supportive information is available. Events are classified as suspected if they have clinical features compatible with the diagnosis but either further investigation is required or additional investigation of the case did not provide supporting evidence for the diagnosis and did not identify an alternative diagnosis. CDC and state health departments also receive reports of other events that are associated temporally with smallpox vaccination. Reported adverse events are not necessarily associated with vaccination, and some or all of these events might be coincidental.
During January 24-February 14, 2003, smallpox vaccine was administered to 4,213 civilian health-care workers in 27 jurisdictions. No potentially life threatening or moderateto-severe adverse events have been reported. Among seven vaccinees with reported nonserious adverse events, the most common signs and symptoms were fever (n = two), rash fatigue, headache, pruritis, local reaction at vaccination site, regional lymphadenopathy, lymphangitis, fever, myalgia and chills, and nausea); additional events are associated temporally with smallpox vaccination but have not been documented to be associated causally with vaccination.
(n = two), malaise (n = two), pruritus (n = two), hypertension (n = two), and pharyngitis (n = two).
Surveillance for adverse events during the civilian smallpox vaccination program is ongoing. Regular surveillance reports will be published in MMWR. 
Notice to Readers

Release of Atlas Highlighting Burden of Stroke Death
Stroke is the third leading cause of death in the United States and the leading cause of serious, long-term disability. Each year, approximately 700,000 U.S. residents experience a new or recurrent stroke; an estimated 500,000 residents will have their first stroke (1) . In 1999, a total of 167,000 deaths from stroke occurred; of these, approximately half occurred out of hospital (2) . A new CDC report, The Atlas of Stroke Mortality: Racial, Ethnic, and Geographic Disparities in the United States (3) provides, for the first time, an extensive series of national and state maps that show local disparities in stroke death rates for the five largest racial/ethnic groups in the United States. The maps provide health-care professionals and concerned persons with county-level maps of stroke mortality that are essential for tailoring stroke-prevention policies and programs to the needs of communities.
High blood pressure and atrial fibrillation are important risk factors for stroke that can be prevented and controlled in reducing stroke-related deaths and disability. CDC funds health departments in 29 states and the District of Columbia to develop effective strategies for reducing the burden of cardiovascular diseases (e.g., heart disease and stroke) with an emphasis on policy and systems changes. Through these statebased programs, CDC aims to eliminate disparities in treatment, risk factors, and disease; delay the onset of disease; postpone death from cardiovascular disease; and diminish disabling conditions. Additional information is available at http://www.cdc.gov/ nccdphp/cvd/stateprogram.htm. Detailed maps of stroke and heart disease mortality at state and county levels are available at http://www.cdc.gov/cvh. Additional information about stroke also is available from the National Institute of Neurological Disorders and Stroke at http://www.ninds.nih.gov, the American Stroke Association Division of the American Heart Association at http://www.strokeassociation.org, the Brain Attack Coalition at http://www.stroke-site.org, and the National Stroke Association at http://www.stroke.org. 
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